Research and Markets: Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Na

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/6528a9/neurodegenerative) has announced the addition of the "Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth" report to their offering.

Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth, which provides insights into the Neurodegenerative Disease Market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major neurodegenerative disease including Alzheimer's disease, Multiple sclerosis, Parkinson disease, Diabetic neuropathy and also orphan neurodegenerative diseases such as Huntington's disease and Amyotrophic lateral sclerosis. The report also provides information on the share of generics in Neurodegenerative Disease Markets and examines the global treatment usage patterns for neurodegenerative diseases. In addition, the geographical distribution of neurodegenerative diseases and therapeutics market across the US, the top five countries of Europe and in Japan. The report also includes insights into the neurodegenerative disease therapeutics research and development (R&D) product pipeline and explores the competitive landscape, including major players in the Neurodegenerative Disease Market. Finally, the report also includes analysis of the Mergers and Acquisitions (M&As) and licensing agreements that have taken place in the Neurodegenerative Disease Market

Anticipated Launch of Novel Molecules Will Drive Growth of the Neurodegenerative Disease Market in Forecast Period

The global neurodegenerative therapeutics market is valued as $16,828m in 2010, and grew from $11,055m in 2002 with a Compound Annual Growth Rate (CAGR) of 5.4%. An increase in the geriatric population globally, along with an increase in life expectancy, is expected to increase the disease population of neurodegenerative diseases. The product pipeline for neurodegenerative disease therapeutics is promising, with many novel molecules with disease modifying characteristics at various stages of clinical development, and these are expected to fulfill the unmet needs in the Neurodegenerative Disease Market. The product pipeline for multiple sclerosis has many orally administered novel molecules, while the Alzheimer's disease therapeutic pipeline has novel molecules such as bapineuzumab, solanezumab, and BMS-708163, which target the underlying causes of the disease and thus may offer significant benefits to patients. The product pipeline also has promising molecules for rare disorders such as Huntington's disease and amyotrophic lateral sclerosis and had shown better safety and efficacy profiles in clinical development. Although in the coming years the market will witness the patent expiries of major drugs, the rapid uptake of new molecules will stabilize the market decline and the market is expected to grow with a CAGR of 5.9% from 2010 to 2017 to reach $25,118m in 2017.

Neurodegenerative Disease Market, Global, Revenue Forecasts ($m), 2002-2017 Source: GBI Research, FDA,EMEA, JAPIC, Rx USA, ZenRx, CDC, ClinicalTrials.gov

Key Topics Covered:

1 Tables & Figures

2 Neurodegenerative Disease Market to 2017 - Introduction

3 Neurodegenerative Disease Market to 2017 - Global Market Overview

4 Neurodegenerative Disease Market to 2017 - Geographical Landscape

5 Neurodegenerative Disease Market to 2017 - Therapeutic Landscape

6 Neurodegenerative Disease Market to 2017 - Product Pipeline Analysis

7 Neurodegenerative Disease Market to 2017 - Competitive Landscape

8 Neurodegenerative Disease Market to 2017 - M&A Landscape

9 Appendix

Companies Mentioned:

  • Teva
  • Biogen Idec
  • Merck Serono
  • Bayer Schering Pharma AG
  • Novartis
  • Boehringer Ingelheim
  • Pfizer

For more information visit http://www.researchandmarkets.com/research/6528a9/neurodegenerative



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.